Harvard Bioscience (HBIO) Short term Debt (2013 - 2025)

Harvard Bioscience (HBIO) has 13 years of Short term Debt data on file, last reported at $34.0 million in Q3 2025.

• Short term Debt for Q3 2025 came in at $34.0 million, up 841.96% year-over-year; the trailing twelve-month figure through Sep 2025 was $34.0 million (up 841.96% YoY), and the FY2024 annual result was $37.0 million, up 530.76% from the prior year.
• Short term Debt eased to $34.0 million in Q3 2025 per HBIO's latest filing, from $34.9 million in the prior quarter.
• Over five years, Short term Debt peaked at $37.0 million in Q4 2024 and troughed at $2.0 million in Q1 2021.
• A 5-year average of $10.0 million and a median of $3.5 million in 2023 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2021 and 2025: Short term Debt retreated 29.82% in 2021, then jumped 866.61% in 2025.
• A 5-year view of Short term Debt shows it stood at $3.2 million in 2021, then advanced by 17.81% to $3.8 million in 2022, then surged by 53.74% to $5.9 million in 2023, then surged by 530.76% to $37.0 million in 2024, then retreated by 8.09% to $34.0 million in 2025.
• Business Quant data shows HBIO's Short term Debt at $34.0 million in Q3 2025, $34.9 million in Q2 2025, and $36.0 million in Q1 2025.